Johnson & Johnson has reached an agreement to settle a misdemeanor criminal charge over the marketing of its antipsychotic drug Risperdal, according to a Bloomberg report.
The Justice Department and U.S. attorney in Philadelphia are continuing to pursue criminal and civil actions against the company after alleging that J&J has marketed the drug for unapproved uses since 2004.
“Discussions have been ongoing in an effort to resolve criminal penalties under the Food Drug and Cosmetic Act related to the promotion of Risperdal,” J&J said, according to the report. “Certain issues remain open before a settlement can be finalized.”
The company is also in negotiations to settle civil investigations over Risperdal and another drug in New Jersey. J&J said it wasn’t sure a settlement could be reached on those claims, according to the report.
Read the Bloomberg report on Johnson & Johnson.
Related Articles on Johnson & Johnson:
Johnson & Johnson to Pay South Carolina $327M for Deceptive Drug Marketing
Johnson & Johnson Reserves Money in Federal Probe Over Risperdal
Massachusetts Files Suit Against Johnson & Johnson Over Risperdal Marketing
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
